| Document |
Document Title |
|
WO/2022/165918A1 |
Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention ...
|
|
WO/2022/169839A1 |
The present disclosure relates to compositions and methods related to modification of trichome density and transport of metabolite and their uses in plants, including tobacco and cannabis. The provided transcription factors enable the in...
|
|
WO/2022/170194A2 |
Compositions and methods for editing, e.g., altering a DNA sequence, within a LAG3 gene are provided. Compositions and methods for immunotherapy are provided.
|
|
WO/2022/168861A1 |
The present invention provides a polypeptide having an amino acid sequence capable of binding to NRP1 and an amino acid sequence capable of inducing apoptosis.
|
|
WO/2022/169863A1 |
The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (g...
|
|
WO/2022/170093A2 |
Disclosed are CAR polypeptides comprising a target specific receptor and a death domain. Disclosed are CAR polypeptides comprising a LINGO 1 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed...
|
|
WO/2022/146891A3 |
Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (p...
|
|
WO/2022/170063A1 |
The disclosure provides recombinant fusion proteins comprising an antigen binding domain specific for CTLA-4, an IL-15Ra sushi domain and IL-15. The disclosure further provides methods of using these recombinant fusion proteins in the tr...
|
|
WO/2022/169984A1 |
This invention relates to methods and compositions for binding antibodies. The methods may be used to isolate antibodies, treat disorders related to excess antibodies, acutely block antibodies to stop an autoimmune or inflammatory respon...
|
|
WO/2022/080865A3 |
The present invention relates to a recombinant dog TRAIL protein, a method of preparing same, an anti-cancer composition for a pet dog, comprising the recombinant dog TRAIL protein, an animal food additive comprising the composition, and...
|
|
WO/2022/166905A1 |
Provided in the present invention is a T cell receptor (TCR), which has the property of binding to a TIHDIILECV-HLA A0201 complex, wherein the binding affinity of the TCR to the TIHDIILECV-HLA A0201 complex is at least twice the binding ...
|
|
WO/2022/165917A1 |
Provided are a transcriptional regulation factor specifically responsive to D-2-hydroxyglutaric acid and an application thereof in biological detection of D-2-hydroxyglutaric acid. The transcriptional regulation factor is named as DhdR, ...
|
|
WO/2022/166904A1 |
The present invention provides a T-cell receptor (TCR) capable of specifically binding to a short peptide TIHDIILECV derived from an HPV16 E6 antigen. The antigenic short peptide TIHDIILECV can form a complex with HLA A0201, and the comp...
|
|
WO/2022/167831A1 |
A method of inducing a protective immune response against Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2), comprising administering to the upper respiratory tract of a subject an effective amount of an agent that induce...
|
|
WO/2022/170184A1 |
A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SE...
|
|
WO/2022/169836A1 |
Composition and methods for the modification of the secondary metabolic functions of glandular trichomes in plants, such as tobacco or cannabis, that control the formation of terpenes that impart specific flavor and aroma characteristics...
|
|
WO/2022/169364A1 |
The invention relates to methods for inhibiting S. suis comprising administering to CATH2 or a derivative thereof and to methods for the treatment or prevention of a S. suis infection in a subject in need thereof, comprising administerin...
|
|
WO/2022/168991A1 |
The purpose of the present invention is to provide: a protein involved in the transport of a fucose-containing sugar; and a method for producing a fucose-containing sugar efficiently using a microorganism capable of producing the protein...
|
|
WO/2022/166026A1 |
A Cre recombinase induction-based large-scale lentiviral gene drug preparation system, which comprises: a suspended 293 stable cell line and a virus that expresses the Cre gene; a lentivirus packaging protein expression sequence and a ta...
|
|
WO/2022/169991A1 |
A colorimetric assay uses a stimuli-responsive peptide for detecting an enzyme. The assay includes a modular peptide having physicochemical properties that change in response to a presence of an enzyme of interest such as a protease. The...
|
|
WO/2022/169875A1 |
Provided herein are compositions and methods for stabilizing enzymes. Also provided are systems, compositions and methods for using the stabilized enzymes to produce a desired compound.
|
|
WO/2022/167003A1 |
Provided is a method for using tangential flow ultrafiltration technology to prepare a controllable high concentration high molecular weight silk fibroin solution. The steps comprise: obtaining a silk fibroin inorganic salt solution; per...
|
|
WO/2022/170196A1 |
The invention provides isolated AIF and PPIA binding peptides that disrupt PPIA/AIF complex formation and/or activity and prevent the resulting death of myocardial cells and to pharmaceutical compositions thereof. The invention further p...
|
|
WO/2022/170044A1 |
Described herein are compositions and methods targeting IL-3 signaling for reducing Alzheimer's disease (AD)-related pathology.
|
|
WO/2022/170119A1 |
Immunogenic compositions that include SARS-CoV-2 spike (S) protein, S1 protein, or S2 protein, and an adjuvant, such as alum, or a combination of CpG oligodeoxynucleotide, Poly I:C, and IL-15, and nanoparticle compositions that include S...
|
|
WO/2022/168889A1 |
When this vaccine is administered to the nasal cavity, etc., a vaccine component stays in the nasal cavity or the pharynx, providing a means for heightening the effects of vaccine administration such as induction of immunity. It was conf...
|
|
WO/2022/170193A2 |
Compositions and methods for editing, e.g., altering a DNA sequence, within a TIM3 gene are provided. Compositions and methods for immunotherapy are provided.
|
|
WO/2022/166728A1 |
Provided is a bispecific antibody, comprising a first antigen-binding moiety and a second antigen-binding moiety, wherein a paired domain of the first antigen-binding moiety comprises an amino acid sequence of engineered HLA-Iα3 and an ...
|
|
WO/2022/165889A1 |
Provided are a PD-1 gene knockout MUC1-targeting CAR-T cell, and a preparation method therefor and the use thereof, belonging to the technical field of cellular immunotherapy. Firstly, an MUC1-targeting chimeric antigen receptor is prepa...
|
|
WO/2022/167729A1 |
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to a cross-hybrid Fc-fusion polypeptide targeting PD-L1, a polynucleotide encoding the Fc-fusion polypeptide, and a vector com...
|
|
WO/2022/166720A1 |
Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fus...
|
|
WO/2022/136442A3 |
The present invention relates to an insecticidal composition comprising: a. at least one cyclic peptide comprising an amino acid sequence of any of: SEQ ID NOs: 1, 2 or 6, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94...
|
|
WO/2022/169339A1 |
The present invention relates to a nucleic acid molecule, including a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen, for prevention or treatment of viral infection or cancer. In addition, the present inven...
|
|
WO/2022/170058A1 |
The present applications discloses an NLS-optimized SpCas9-based prime editor that improves genome editing efficiency exemplified by endogenous loci in cultured cell lines. Using this genome modification system, tumor formation can be in...
|
|
WO/2022/167000A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a polypeptide fragment C and an application thereof, the polypeptide fragment C having the amino acid sequence shown in SEQ ID NO. 1, wherei...
|
|
WO/2022/170179A1 |
The present invention features methods and compositions directed towards a recombinant polypeptide biopolymer composition that are effective as nano springs. The composition of the present invention comprises both a streptavidin polypept...
|
|
WO/2022/169258A1 |
The present invention relates to cell-derived vesicles with increased cellular uptake capacity and a method for producing same. The cell-derived vesicles of the present invention are produced by migrating cells to micropores, and exhibit...
|
|
WO/2022/166999A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a polypeptide fragment B and an application thereof, the polypeptide fragment B having the amino acid sequence shown in SEQ ID NO. 1, wherei...
|
|
WO/2022/155526A3 |
Hybrid and truncated immune cell proteins are described. Hybrid proteins are stimulatory and include an extracellular domain of one stimulatory immune cell protein, an intracellular domain of a different stimulatory immune cell protein, ...
|
|
WO/2022/169206A1 |
The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipi...
|
|
WO/2022/165608A1 |
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the su...
|
|
WO/2022/169291A1 |
The present invention relates to modified killer cells, a preparation method therefor, and a pharmaceutical use thereof. More specifically, in the present invention, killer cells genetically modified to express a chemokine receptor, a cy...
|
|
WO/2022/170344A1 |
Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can for example be suffering from immune disord...
|
|
WO/2022/140321A3 |
Provided herein are T-cell receptors (TCRs) that when expressed recombinantly on the surface of a T cell are able to recognize the MAGE-B2-derived peptide GVYDGEEHSV (SEQ ID NO:1) when presented by HLA-A*02:01 sufficiently to activate th...
|
|
WO/2022/170172A1 |
Compositions and methods for editing, e.g., altering a DNA sequence, within a 2B4 gene are provided. Compositions and methods for immunotherapy are provided.
|
|
WO/2022/165982A1 |
The present application provides a method and a kit for detecting a coronavirus antibody by means of immunoturbidimetry. The detection of a neutralizing antibody is achieved on a latex platform by using a multimeric RBD or a polyploid RBD.
|
|
WO/2022/166806A1 |
Provided is a novel CD271-based antigenic epitope peptide. The epitope peptide is: (1) located in SEQ ID NO.1; or (2) located in an amino acid sequence having at least 80% identity with the sequence SEQ ID NO.1 in (1), SEQ ID NO.1 contai...
|
|
WO/2022/169594A1 |
The invention is directed to compositions and methods for collecting, transporting, and storing, preferably without refrigeration, biological materials, which may comprise samples of biological, clinical, forensic, and/or environmental o...
|
|
WO/2022/166027A1 |
Provided is a system for producing an AAV genetic medicine by infection of an insect cell using a baculovirus. The system comprises: a first baculovirus, a second baculovirus, a third baculovirus, and an Sf9 cell; an expression cassette ...
|
|
WO/2022/170177A1 |
Provided according to embodiments of the invention are fusion proteins comprising receptor binding domain polypeptides and receptor polypeptides linked to reporter enzyme fragments. The invention further relates to polynucleotides and ve...
|
